Answers are grounded in this paper and cite their sources.
Eplerenone, as compared with placebo, reduced both the risk of death and the risk of hospitalization among patients with systolic heart failure and mild symptoms. (Funded by Pfizer; ClinicalTrials.gov number, NCT00232180.).
No takes yet. Share an insight, caveat, or question.
Zannad et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: